Clinical Research of Adefovir Dipivoxil or Lamivudine on Patients with Pulmonary Tuberculosis Combined with Type B Hepatitis

OBJECTIVE To observe the efficacy on patients with pulmonary tuberculosis combined with type B hepatitis treated by adefovir dipivoxil or lamivudine. METHODS The efficacy on 112 patients with pulmonary tuberculosis combined with type B hepatitis treated by adefovir dipivoxil or lamivudine was retrospectively analyzed, and 2HREZ/7HRE method was used to treat antituberculosis. RESULTS Compared with lamivudine treated group, the serum HBV-DNA copy number of adefovir dipivoxil treated group was noticeably reduced after 6 or 12 months treatment(P<0.05); the liver function index of both groups were significantly decreased, but without any significant differences. CONCLUSION During antituberculosis treatment on patients with pulmonary tuberculosis combined with type B hepatitis, compared with lamivudine treated group, application of adefovir dipivoxil can more effectively inhibit hepatitis B virus replication, alleviate virus on liver damage, enhance drug tolerability on patients with liver tuberculosis, and improve patient's liver function, so that the patients can successfully complete the antituberculosis treatment.